Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 1/20 | 0.47 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.47 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.47 |
| ▸ | MBOAT4 | Q96T53 | 3/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 8/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 8/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.35 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2195019 | 0.87 | CDK5 (0.48) | CDK5CDK5R1NR1I3MBOAT4GRIN1 | |
| SCHEMBL26060781 | 0.86 | NR1I3 (0.50) | CDK5CDK5R1NR1I3MBOAT4GRIN1 | |
| SCHEMBL10878141 | 0.86 | NR1I3 (0.50) | CDK5CDK5R1NR1I3MBOAT4GRIN1 | |
| SCHEMBL10878132 | 0.86 | NR1I3 (0.50) | CDK5CDK5R1NR1I3MBOAT4GRIN1 | |
| SCHEMBL11580475 | 0.86 | NR1I3 (0.50) | CDK5CDK5R1NR1I3MBOAT4GRIN1 | |
| SCHEMBL31620148 | 0.83 | NR1I3 (0.48) | CDK5CDK5R1NR1I3MBOAT4GRIN1 | |
| SCHEMBL28302658 | 0.83 | CDK5 (0.45) | CDK5CDK5R1NR1I3MBOAT4GRIN1 | |
| SCHEMBL10886068 | 0.83 | CDK5 (0.48) | CDK5CDK5R1NR1I3MBOAT4GRIN1 | |
| SCHEMBL10886062 | 0.83 | CDK5 (0.48) | CDK5CDK5R1NR1I3MBOAT4GRIN1 | |
| SCHEMBL27317899 | 0.80 | GRIN1 (0.55) | CDK5CDK5R1NR1I3MBOAT4GRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050049231-A1 | Local delivery of aromatase inhibitor using intravaginal device; estrogen dependent proliferative disorders of uterus; minimal side effects, longer term treatment, variable dosage | ARES TRADING, S.A. (CH) | 2005-03-03 | — | — | US | claimed |
| EP-1423165-A2 | INTRAVAGINAL ADMINISTRATION OF AN AROMATASE INHIBITOR FOR THE TREATMENT OF OESTROGEN-DEPENDENT PROLIFERATIVE DISORDERS | Metris Therapeutics Limited (GB) | 2004-06-02 | — | — | EP | claimed |
| US-6696432-B1 | SYNERGYSTIC MIXTURES OF PRASTERONE, PREFERENTIAL ENZYME INHIBITORS SUCH AS FORMESTANE, TESTOLACTONE OR VOROZOLE AND CARRIERS, ADMINISTERED FOR PROPHYLAXIS OF HYPOANDROGENISM | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-02-24 | — | — | US | claimed |
| WO-2003015872-A2 | INTRAVAGINAL ADMINISTRATION OF AN AROMATASE INHIBITOR FOR THE TREATMENT OF OESTROGEN-DEPENDENT PROLIFERATIVE DISORDERS | METRIS THERAPEUTICS LIMITED (GB) | 2003-02-27 | — | — | WO | claimed |
| US-5733902-A | Compounds having antiprogestational and anti-estrogenic activities for the treatment of hormone-dependent tumors | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-03-31 | — | — | US | claimed |
| EP-0100566-B1 | NOVEL 19-THIO-ANDROSTANE DERIVATIVES | AKZO N.V. (NL) | 1986-02-19 | — | — | EP | claimed |
| US-4473564-A | 19-Thio-androstane derivatives | AKZO N.V. (NL) | 1984-09-25 | — | — | US | claimed |
| EP-0100566-A1 | Novel 19-thio-androstane derivatives | AKZO N.V. (NL) | 1984-02-15 | — | — | EP | claimed |
| US-7910570-B2 | Composition comprising a combination of an aromatase inhibitor, a progestin and an oestrogen and its use for the treatment of endometriosis | ASTRAZENECA AB (SE) | 2011-03-22 | — | — | US | disclosed |
| US-20110009373-A1 | COMPOSITION COMPRISING A COMBINATION OF AN AROMATASE INHIBITOR, A PROGESTIN AND AN OESTROGEN AND ITS USE FOR THE TREATMENT OF ENDOMETRIOSIS | ASTRAZENECA AB (SE) | 2011-01-13 | — | — | US | disclosed |
| EP-1857111-A2 | Composition comprising a combination of an aromatase inhibitor, a progestin and an estrogen, and its use for the treatment of endometriosis | AstraZeneca AB (SE) | 2007-11-21 | — | — | EP | disclosed |
| EP-1589976-B1 | USE OF A COMBINATION OF AN AROMATASE INHIBITOR, A PROGESTIN AND AN OESTROGEN FOR THE TREATMENT OF ENDOMETRIOSIS | ASTRAZENECA AB (SE) | 2007-10-03 | — | — | EP | disclosed |
| US-20060142256-A1 | Composition comprising a combination of an aromatase inhibitor, a progestin and an oestrogen and its use for the treatment of endometricosis | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | US | disclosed |
| EP-1589976-A1 | COMPOSITON COMPRISING A COMBINATION OF AN AROMATASE INHIBITOR, A PROGESTIN AND AN OESTROGEN AND ITS USE FOR THE TREATMENT OF ENDOMETRIOSIS | Astrazeneca AB (SE) | 2005-11-02 | — | — | EP | disclosed |
| US-4473564-A | 19-Thio-androstane derivatives | AKZO N.V. (NL) | 1984-09-25 | — | — | US | disclosed |
| US-4473564-A | 19-Thio-androstane derivatives | AKZO N.V. (NL) | 1984-09-25 | — | — | US | disclosed |
| US-4473564-A | 19-Thio-androstane derivatives | AKZO N.V. (NL) | 1984-09-25 | — | — | US | disclosed |
| EP-0100566-A1 | Novel 19-thio-androstane derivatives | AKZO N.V. (NL) | 1984-02-15 | — | — | EP | disclosed |
| EP-0100566-A1 | Novel 19-thio-androstane derivatives | AKZO N.V. (NL) | 1984-02-15 | — | — | EP | disclosed |
| EP-0100566-A1 | Novel 19-thio-androstane derivatives | AKZO N.V. (NL) | 1984-02-15 | — | — | EP | disclosed |